Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Table 4 Availability of measurements in the recruited patient dataset

Potential covariate	Availability (number of patients, out of 54)
Age	54
Breslow thickness	43
LDH	51
LY%	53
SOD at the baseline^a	54
Cutaneous malignant melanoma (Y/N)	52
Nodular melanoma (Y/N)	52
BRAF V600 mutation (Y/N)	46

Measurements of parameters that are potential covariates for determination of the personal models (Y/N refers to a test outcome)
^aSum of diameters of measurable lesions at the baseline, as defined by RECIST 1.1 [40]

ISSN: 1479-5876